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obesity directly, but a corresponding decrease in resources used to treat co-mor-
bidities.
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OBJECTIVES: Obesity has reached epidemic proportions and has many cost impli-
cations. Being overweight and obese is associated with higher rates of many
chronic health conditions, which in turn leads to increases in medical spending
and productivity losses. Many worksites have implemented weight management
programs for employees to offset the cost burden of disease. This study modeled
the potential cost savings for an employer from a 2-year worksite weight manage-
ment program over ten year time horizon. METHODS: We used data from a group
randomized control trial of a worksite weight management program and published
healthcare utilization data to model long term net costs. Using a Markov decision
analytic modeling technique, we conducted a cost benefit analysis of weight man-
agement program versus usual practice. Program costs, health care utilization and
prevalence of overweight and obesity in the study population were used to assess
program impact. Sensitivity analyses were conducted to find a threshold at which
the intervention would have a positive net benefit. RESULTS: The study population
showed had a 1.44% decrease in the overweight/obesity in one year. When modeled
over 10 years, this program incurred an excess cost of $206 per person compared to
usual practice. The threshold at which this program would have a positive net
benefit is when there is a 5.8% decrease in the overweight/obese population
annually. CONCLUSIONS: Worksite weight management programs may yield cost
savings with modest reduction in the percentage of overweight or obese employ-
ees. This evidence may encourage employers to implement and support weight
management programs that have empirically demonstrated higher rates of weight
loss in employees. More research is needed to understand why some individuals
are more successful at weight reduction and to evaluate long-term effectiveness of
weight management at worksites.
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OBJECTIVES: Romiplostim stimulates platelet production via the thrombopoetin-
receptor and is recommended for second- and third-line treatment of chronic ITP
in adults. Traditional treatment options in this setting have included unapproved
use of the immunosuppressant rituximab. This analysis assessed the cost per re-
sponder of romiplostim compared to rituximab in adult ITP patients in France.
METHODS: A decision analytic model was developed to estimate the six-month
cost per patient responding to treatment. A systematic literature review was per-
formed to obtain response rates (achieving a platelet count 50x109/L) for each
treatment. Romiplostim patients received weekly administrations; rituximab pa-
tients received 4 weekly intravenous infusions. Resource utilization was based on
French and international treatment guidelines, and clinical expert opinion. Unit
costs were derived from published literature and French reimbursement lists, and
included the costs of routine physician visits, treatment administration and emer-
gency care. Non-responders incurred the cost of rescue therapy (IVIg and predni-
sone) and hospitalizations/physician visits associated with bleeding-related
events (BREs). RESULTS:Although the comparability of existing literature for romi-
plostim and rituximab was limited, several fulfilled the literature review selection
criteria. Response rates were 83% and 62.5%, as per the romiplostim pivotal trial
and a meta-analysis on rituximab, respectively. Mean cost per patient for romi-
plostim and rituximab was €17,486 and €17,086 respectively. Dividing mean cost
per patient by response rates, cost per response was €27,337 for romiplostim and
€25,178 for rituximab. The main cost-offsets were due to reduced rescue therapy
and BREs, with romiplostim resulting in a 23% reduction in cost per platelet re-
sponse. Across sensitivity analyses, romiplostim consistently produced a lower
cost per response.CONCLUSIONS: In adult ITP patients, romiplostim yields a lower
cost per response over 6 months compared to rituximab, indicating romiplostim
represents an efficient use of resources for the French health care system.
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OBJECTIVES: Continuous wound infiltration (CWI), intravenous patient controlled
analgesia (iv-PCA) and epidural analgesia (EDA) are analgesic techniques com-
monly used for pain relief after open abdominal surgery. The aim of this study was
to evaluate the cost-impact and cost-effectiveness of these analgesic techniques.
METHODS: A decision tree model was developed in which patients entered after
successful colorectal surgery and received post-operative analgesia. The pathways
consist of a number of particular events including patient eligibility given their
agreement to benefit from the technique, rate of intra-operative technical failure,
successful pain relief and potential adverse events. Data was retrieved from clini-
cal trials and from an observational prospective cohort of 85 patients. Efficacy
criteria were based on pain at mobilisation. Healthcare resource use and costs were
evaluated from medical records measurements and published data. The incremen-
tal cost-effectiveness ratio (ICER) was expressed as the ratio between differential
total cost of procedures and differential efficacy. Probabilistic sensitivity analysis
(PSA) was performed around the willingness to pay per controlled patient.
RESULTS: When taking into account all the healthcare resources consumed, the
CWI arm (€4,044) is economically dominant compared to iv-PCA (€4,779). EDA is
more costly, but also more effective than CWI, with an estimated ICER of €27,446 for
each additional controlled patient. PSA analysis shows that CWI remains cost-
saving in 71.3% of cases. CONCLUSIONS:Device-related costs of using CWI for pain
management after abdominal laparotomy are partly counterbalanced by a reduc-
tion in healthcare resource consumption. It is also important to consider that a
proportion of patients do not have the capacity to benefit from epidural techniques
and some may also refuse the technique. This economic evaluation may be useful
for clinicians to design algorithms for pain management after major abdominal
surgery.
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OBJECTIVES: About 5% of the population (400,000 in Austria) suffer from neuro-
pathic pain. Fifty percent of them denominate their pain as “very strong”. Neuro-
pathic pain patients consult on average 5 different doctors before the main diag-
nosis is found. The aim of this study was to evaluate the cost-effectiveness of
treatment of neuropathic pain with topical Capsaicin Patch 8% versus current stan-
dard of care (pregabalin) in Austria. METHODS: The analysis was performed using
a Decision Tree Model combined with a Markov model adapted for Austria. The
model is based on an indirect comparison, which results in a conservative estima-
tion, as the efficacy of capsaicin patch 8% is underestimated due to a large placebo
effect. Efficacy assessment was based on the outcome measure QALY. Costs were
captured for the year 2011. Resource use was determined by literature research and
expert opinion and accurately reflects the Austrian treatment path. The study time
horizon was 5 years. The analysis was performed from the perspective of social
health insurance. The analysis was conducted according to Austrian Guidelines for
Health Economic Evaluations. RESULTS: The results are shown for a time horizon
of 5 years. The cost per patient (30% pain reduction) for capsaicin patch 8% amount
to €4898 for a time horizon of 5 years and to €4745 for Pregabalin. Treatment with
capsaicin patch 8% leads to 3.011 QALYs, treatment with Pregabalin to 2.964 QALYs.
The cost per QALY is €1627 (capsaicin patch 8%) versus €1611 (Pregabalin) with an
ICER of €2358. CONCLUSIONS: In Austria, the treatment of neuropathic pain with
Capsaicin Patch 8% is a cost-effective alternative compared to Pregabalin from the
perspective of the social health insurance.
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COST EFFECTIVENESS OF TRAMADOL VERSUS DICLOPHENAC IN PAIN
MANAGEMENT AFTER CESAREAN DELIVERY
Farshchi A, Farshchi S, Merrikhi Haghi S
Tehran University of Medical Sciences, Tehran, Iran
OBJECTIVES: Postoperative pain is one of the main adverse outcomes causing dis-
tress to patients after cesarean delivery. Meanwhile the main analgesic drugs are
opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), more over side effects
such as nausea, vomiting, sedation were reported with opioids. METHODS: This
study was undertaken based on our clinical trial that evaluated postoperative pain
in a double-blinded, randomized, single-dose comparison of Tramadol IM injec-
tion, 100 mg (Group T) and Diclophenac suppository, 100 mg (Group D) given alone-
single dose in 100 patients who had elective cesarean delivery. All patients were
assessed at 0, 6, 12 and 24 hours post operation for pain degree (by Visual Analogue
Score: VAS 1-10), nausea and vomiting. Our outcomes were the reduction in pain.
For the cost estimates of therapeutic schemes, we computed the direct costs of the
analgesics (unitary cost) and disposable material (needles, syringes, padcol). Cost-
Effectiveness Ratio was calculated. RESULTS: The efficacy of Tramadol and Diclo-
phenac were not different significantly (P0.06). Nausea and vomiting were mini-
mal with all treatments. Total costs in T group were $52.38 and in D group were
$161.90. Cost-Effectiveness Ratio of Tramadol to Diclophenac was 2.76.
CONCLUSIONS: Cost-Effectiveness Ratio showed that the cost of Tramadol in this
study was 2.76 times more than Diclophenac with the same efficacy, thus the
analgesic effect of Diclophenac is more cost-effective than Tramadol.
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OBJECTIVES: To assess the cost effectiveness of tapentadol PR compared with
oxycodone CR for the treatment of patients with chronic severe non-cancer pain in
Ireland.METHODS:A Markov model was developed to assess the costs and benefits
of tapentadol PR and oxycodone CR treatment over a 1 year time horizon from the
Health Service Executive perspective (GMS and DP/LTI Scheme). Patients tolerating
the treatment or having mild adverse events remained on tapentadol or oxy-
codone. Patients who were lacking efficacy or had poor tolerability switched to
either transdermal fentanyl or morphine. 3rd line therapy was defined as absorb-
ing state. Data regarding efficacy, tolerability and utility values (EQ-5D) were de-
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rived from the 3 phase III clinical trials of tapentadol PR in osteoarthritis and lower
back pain and published literature. Switch rates to 2nd line therapies and co-
medication costs were provided by the National Centre of Pharmacoeconomics
based on the GMS database analysis. Costs of physician visits were obtained by
applying local costs to the number of physician visits in each therapy line obtained
from a retrospective analysis of the UK THIN database of GP patient records. One-
way deterministic and probabilistic sensitivity analyses were undertaken to assess
the impact of parameter uncertainty. RESULTS: Mean annual total costs per pa-
tient from GMS Scheme perspective amount to 4,367€ for tapentadol vs. 4,381€ for
oxycodone. Tapentadol generates 0.6316 QALYs compared to 0.6122 QALYs for
oxycodone, resulting in tapentadol being a dominant treatment. For DP/LTI
Scheme, tapentadol had an ICER of 1,662 €/QALY gained. Results were robust in a
broad range of sensitivity analyses. Probability that tapentadol is cost-effective vs.
oxycodone at threshold of 20,000 €/QALY gained exceeded 95%. CONCLUSIONS:
Compared to oxycodone CR, the most commonly used oral drug for chronic severe
non-cancer pain in Ireland, tapentadol PR appears to be a highly cost-effective
treatment option.
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OBJECTIVES:To assess the cost-effectiveness of tapentadol PR compared to opioids
(morphine, oxycodone, transdermal buprenorphine [TDB] and transdermal fenta-
nyl [TDF]) for the treatment of severe chronic non-cancer pain from the societal
perspective in Portugal. METHODS: A one year Markov transition state model with
monthly cycles was built. Four health states were defined: ‘no withdrawal and no
adverse events treated’, ’occurrence of adverse events (AEs) with need for medical
treatment’, ’withdrawal due to AEs’, and ‘withdrawal due to lack of efficacy’. If
patients did not adequately respond to treatment or withdraw, switching to alter-
native second line opioid (morphine, hydromorphone, TDB or TDF) was consid-
ered. Third line therapy was the absorption state. Data regarding efficacy, tolera-
bility and utility values (EQ-5D) were derived from clinical trials and published
literature. Switch rates to subsequent opioid therapies and resource consumption
were estimated by clinical experts. Costs were calculated from the societal per-
spective. Direct costs were calculated based on official Portuguese prices/tariffs,
indirect costs derived from the National Health Survey. One-way and probabilistic
sensitivity analyses were conducted. RESULTS:Mean annual total costs per patient
amounted to 3793 € for morphine, 3,804€ for TDF, 3891 € for TDB, 3964 € for oxy-
codone, and 4117 € for tapentadol. Total QALYs generated were 0.6102 (morphine),
0.6062 (TDF), 0.6026 (TDB), 0.6096 (oxycodone), and 0.6287 (tapentadol). The result-
ing ICERs (€/QALY gained) for tapentadol yield 7,995 versus oxycodone, 8,685 versus
TDB, 13,943 versus TDF, and 17,547 versus morphine. Varying costs, probabilities,
and utilities by 50%, 10%, and 10%, respectively, resulted in an ICER range
from tapentadol being dominant (vs. oxycodone) to 26,000 €/QALY gained (vs.
morphine). CONCLUSIONS: To improve pain relief and quality of life in patients
with severe chronic pain tapentadol appears to be the favourable and cost-effective
treatment option from the societal perspective in Portugal.
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OBJECTIVES: The emergence of new drugs for the treatment of patients with
chronic idiopathic thrombocytopenic purpura (ITP), stimulates the proliferation of
megakaryocyte germ (eltrombopag), stresses the need to conduct a comparative
analysis in their cost-effectiveness, compared with other modern treatment
options. METHODS: Markov modeling was used. Markov model, developed by
GlaxoSmithKline, was adapted to the context of Russian health care system to
assess cost-utility and cost-effectiveness of eltrombopag and romiplostim for
treatment of chronic ITP in patients, for whom splenectomy is contradicted. El-
trombopag and romiplostim were used as first-line options. The simulation was
performed taking into account the time perspective for 2 years, 10 and 20 years.
Data about diagnosis and treatment of ITP in “real world” settings was collected by
interviewing 5 expert-hematologists with expertise in the treatment of chronic ITP,
working in different health facilities in Russia. Only direct medical costs were
calculated. RESULTS: Cost-effectiveness ratio for criterion “additional years of life”
after 2 years of onset was $27,703 for eltrombopag and $31,988 for romiplastim,
after 10 years of onset – $21,758 and $24,700 respectively, after 20 years of onset –
$17,257 and $19,577 respectively. Cost of QALY after 2 years of onset was $39,000 for
eltrombopag and $45,530 for romiplastim, after 10 years of onset – $35,108 and
$40,218 respectively, after 20 years of onset – $32 527 and $37,204 respectively.
CONCLUSIONS: Eltrombopag is cost-effective compared with romiplostim as a
first-line therapy in treatment of chronic idiopathic thrombocytopenic purpura in
patients, for whom splenectomy is contradicted.
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OBJECTIVES: To conduct an economic evaluation comparing, ferinject (Ferric Car-
boxymaltose) with Venofer (iron sucrose), iron sucrose similars (ISS-generic forms
of iron sucrose) and Cosmofer (low molecular weight-LMW iron dextran) in the
management of anaemia patients in Greece.METHODS:A cost-minimization anal-
ysis, from National Health System (NHS) perspective, was conducted since there
are no clear data indicating that one of these regimens is superior to the others in
terms of efficacy. Because iron could be administered either to inpatients (i.e.,
surgical patients or patients hospitalized due to a disease related to chronic or
acute blood loss) or to outpatients (i.e. non-dialysis chronic kidney disease patients
etc), the economic evaluation was undertaken for these two large categories of
patients, separately. Total cost related to each treatment includes the cost of drugs,
the cost of disposables for each infusion, the monitoring cost during infusion (sal-
aries of personnel), the cost for management of adverse events, the cost of visits,
the productivity loss, and the travelling cost of patients. A supplementary budget
impact analysis was also conducted. RESULTS: The mean total (direct) cost of
therapy with Ferric Carboxymaltose was €216.32, in the iron sucrose arm the cost
was €296.34, in the LMW iron dextran arm was €251.12, while in the ISS the cost was
estimated at €324.47 for inpatients. In the case of outpatients the cost of ferric
carboxymaltose was €152.66, the cost of iron sucrose was €285.10, the cost of LMW
iron dextran was €459.88 and the cost of ISS was estimated at €313.13. Various
sensitivity analyses showed that the main results were robust, reaching a statisti-
cal significant difference in 95% level of significance. CONCLUSIONS: Ferric Car-
boxymaltose represents a cost-saving option compared with other alternative
therapies used in the management of anaemia in the National Health Service of
Greece.
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OBJECTIVES: To conduct an economic evaluation for End Stage Renal Disease
(ESRD) diabetic and non diabetic patients treated with Darbepoetin alfa, Epoetin
alfa, Epoetin beta and Epoetin Beta (Methoxy polyetylene Glycol). METHODS: A
cost-minimization analysis was conducted since there are no clear data indicating
differences in terms of efficacy. A probabilistic Markov model was constructed to
simulate during a 20-year time span the progress of patients through four health
states: “dialysis”, “transplantation”, “dialysis after graft failure” and “death”. The
dose required to maintain the desirable Hb level (10 – 12 g/dL) was obtained from
the literature alongside transition probabilities for the baseline cohort (mean age
65, diabetics 54%). Costs were estimated from the perspective of the healthcare
system and reflect the drug administration, the monitoring of patients, transplan-
tations and other resources consumed by patients valued at €2011. A 3.5% discount
rate was used for outcomes. RESULTS: The mean survival (common for all com-
parators) expressed in terms of QALY’s was 2.16 (95%Uncertainty Interval (UI):
2.11-2.21) overall, and 2.23 (95%UI: 2.18-2.29) and 2.10 (95%UI: 2.05-2.14) for patients
without and with diabetes, respectively. The mean total treatment cost for patients
on Darbepoetin alfa was 11,505 (95%UI: €11,322-€11,680) for the entire population,
€11,103 (95%UI: €10,906-€11,299) for diabetic and €11,976 (95%UI: €11,739-€12,197)
for non-diabetic patients. The mean cost of patients on Epoetin alfa was €15,340
(95%UI: €15,118-€15,554), €14,720 (95%UI: €14,466-€14,976), and €16,068 (95%UI:
€15,760-€16,343) respectively. The cost of Epoetin beta was €15,038 (95%UI: €14,783-
€15,292), €14,435 (95%UI: €14,160-€14,707) and €15,746 (95%UI: €15,434-€16,063) re-
spectively. Finally, for patients on Epoetin Beta (Methoxy polyetylene Glycol), it was
€12,057 (95%UI: €11,868-€12,238), €11,624 (95%UI: €11,416-€11,823) and €12,566
(95%UI: €12,320-€12,796) respectively. CONCLUSIONS:Darbepoetin alfa (AranespÒ)
may represent a cost saving option, compared to other alternative therapies used
in the management of ESRD patients in the National Health Service of Greece.
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OBJECTIVES: Obesity represents a considerable and increasing health problem.
The objective of this research was to assess the clinical and cost-effectiveness of
orlistat in overweight and obese patients in primary care. METHODS: A cohort
simulation model was built in Simul8 to explore the potential benefits of treatment
with orlistat compared with standard care. The model used a lifetime horizon to
estimate the incremental cost per quality adjusted life-year (QALY) gained. Clinical
effectiveness was modelled using the results of a mixed treatment comparison.
Longitudinal analyses of the General Practice Research Database (n100,000) were
used to derive BMI related estimates for times to death, primary myocardial infarc-
tion or stroke, onset of type 2 diabetes, and to estimate the natural history of body
mass index (BMI) in people who are obese. Annual probabilities of subsequent
cardiovascular events were estimated using data from the Nottingham Heart At-
tack register and South London Stroke register. Health related quality of life values
were modelled using a relationship between BMI and EQ-5D data controlling for age
an comorbidities. Current event and post-event health states were used to incor-
porate changes in health related quality of life and costs. RESULTS: Deterministic
analysis gave a cost per QALY gained (versus placebo) of £1,665, although this figure
is sensitive to the baseline BMI, due to the strong correlation of BMI and the risk of
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